{"count": 196, "results": [{"_id": "34343108", "pmid": 34343108, "pmcid": "PMC8428086", "title": "Metformin improves glycemic variability in adults with type 1 diabetes mellitus: an open-label randomized control trial", "journal": "Endocr Connect", "authors": ["Zhang X", "Xu D", "Xu P", "Yang S", "Zhang Q", "Wu Y", "Yuan F"], "date": "2021-08-30T00:00:00Z", "doi": "10.1530/EC-21-0146", "meta_date_publication": "2021 Aug 30", "meta_volume": "10", "meta_issue": "9", "meta_pages": "1045-1054", "score": 50281.754, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ has been demonstrated to enhance cardioprotective benefits in @<m>DISEASE_Diabetes_Mellitus_Type_1</m> @DISEASE_MESH:D003922 @@@type 1 diabetes@@@ (@<m>DISEASE_Diabetes_Mellitus_Type_1</m> @DISEASE_MESH:D003922 @@@T1DM@@@). ", "citations": {"NLM": "Zhang X, Xu D, Xu P, Yang S, Zhang Q, Wu Y, Yuan F. Metformin improves glycemic variability in adults with type 1 diabetes mellitus: an open-label randomized control trial Endocr Connect. 2021 Aug 30;10(9):1045-1054. PMID: 34343108", "BibTeX": "@article{34343108, title={Metformin improves glycemic variability in adults with type 1 diabetes mellitus: an open-label randomized control trial}, author={Zhang X and Xu D and Xu P and Yang S and Zhang Q and Wu Y and Yuan F}, journal={Endocr Connect}, volume={10}, number={9}, pages={1045-1054}}"}}, {"_id": "33457425", "pmid": 33457425, "pmcid": "PMC7785393", "title": "Effects of Metformin Added to Insulin in Adolescents with Type 1 Diabetes: An Exploratory Crossover Randomized Trial", "journal": "J Diabetes Res", "authors": ["Yang D", "Yan J", "Deng H", "Yang X", "Luo S", "Zheng X", "Lv J", "Liang W", "Hong M", "Wu Z", "Yao B", "Weng J", "Xu W"], "date": "2020-12-24T00:00:00Z", "doi": "10.1155/2020/7419345", "meta_date_publication": "2020", "meta_volume": "2020", "meta_issue": "", "meta_pages": "7419345", "score": 50278.965, "text_hl": "Effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Added to @GENE_INS @GENE_3630 @@@Insulin@@@ in Adolescents with @<m>DISEASE_Diabetes_Mellitus_Type_1</m> @DISEASE_MESH:D003922 @@@Type 1 Diabetes@@@: An Exploratory Crossover Randomized Trial", "citations": {"NLM": "Yang D, Yan J, Deng H, Yang X, Luo S, Zheng X, Lv J, Liang W, Hong M, Wu Z, Yao B, Weng J, Xu W. Effects of Metformin Added to Insulin in Adolescents with Type 1 Diabetes: An Exploratory Crossover Randomized Trial J Diabetes Res. 2020;2020():7419345. PMID: 33457425", "BibTeX": "@article{33457425, title={Effects of Metformin Added to Insulin in Adolescents with Type 1 Diabetes: An Exploratory Crossover Randomized Trial}, author={Yang D and Yan J and Deng H and Yang X and Luo S and Zheng X and Lv J and Liang W and Hong M and Wu Z and Yao B and Weng J and Xu W}, journal={J Diabetes Res}, volume={2020}, pages={7419345}}"}}, {"_id": "35707462", "pmid": 35707462, "pmcid": "PMC9190285", "title": "Effect and Safety of Adding Metformin to Insulin Therapy in Treating Adolescents With Type 1 Diabetes Mellitus: An Updated Meta-Analysis of 10 Randomized Controlled Trials", "journal": "Front Endocrinol (Lausanne)", "authors": ["Liu Y", "Chen H", "Li H", "Li L", "Wu J", "Li H"], "date": "2022-05-30T00:00:00Z", "doi": "10.3389/fendo.2022.878585", "meta_date_publication": "2022", "meta_volume": "13", "meta_issue": "", "meta_pages": "878585", "score": 50278.215, "text_hl": "...The role of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in the treatment of adolescents with @<m>DISEASE_Diabetes_Mellitus_Type_1</m> @DISEASE_MESH:D003922 @@@type 1 diabetes mellitus@@@ (@<m>DISEASE_Diabetes_Mellitus_Type_1</m> @DISEASE_MESH:D003922 @@@T1DM@@@) remains controversial. ", "citations": {"NLM": "Liu Y, Chen H, Li H, Li L, Wu J, Li H. Effect and Safety of Adding Metformin to Insulin Therapy in Treating Adolescents With Type 1 Diabetes Mellitus: An Updated Meta-Analysis of 10 Randomized Controlled Trials Front Endocrinol (Lausanne). 2022;13():878585. PMID: 35707462", "BibTeX": "@article{35707462, title={Effect and Safety of Adding Metformin to Insulin Therapy in Treating Adolescents With Type 1 Diabetes Mellitus: An Updated Meta-Analysis of 10 Randomized Controlled Trials}, author={Liu Y and Chen H and Li H and Li L and Wu J and Li H}, journal={Front Endocrinol (Lausanne)}, volume={13}, pages={878585}}"}}, {"_id": "33598651", "pmid": 33598651, "pmcid": "PMC7868998", "title": "The use of metformin as an add-on therapy to insulin in the treatment of poorly controlled type 1 diabetes mellitus in adolescents", "journal": "Metabol Open", "authors": ["Sikorskaya K", "Zarzecka I", "Ejikeme U", "Russell J"], "date": "2021-01-28T00:00:00Z", "doi": "10.1016/j.metop.2021.100080", "meta_date_publication": "2021 Mar", "meta_volume": "9", "meta_issue": "", "meta_pages": "100080", "score": 50277.688, "text_hl": "The use of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ as an add-on therapy to @GENE_INS @GENE_3630 @@@insulin@@@ in the treatment of poorly controlled @<m>DISEASE_Diabetes_Mellitus_Type_1</m> @DISEASE_MESH:D003922 @@@type 1 diabetes mellitus@@@ in adolescents", "citations": {"NLM": "Sikorskaya K, Zarzecka I, Ejikeme U, Russell J. The use of metformin as an add-on therapy to insulin in the treatment of poorly controlled type 1 diabetes mellitus in adolescents Metabol Open. 2021 Mar;9():100080. PMID: 33598651", "BibTeX": "@article{33598651, title={The use of metformin as an add-on therapy to insulin in the treatment of poorly controlled type 1 diabetes mellitus in adolescents}, author={Sikorskaya K and Zarzecka I and Ejikeme U and Russell J}, journal={Metabol Open}, volume={9}, pages={100080}}"}}, {"_id": "32606605", "pmid": 32606605, "pmcid": "PMC7306576", "title": "Metformin Decreases Insulin Resistance in Type 1 Diabetes Through Regulating p53 and RAP2A in vitro and in vivo", "journal": "Drug Des Devel Ther", "authors": ["Ren GF", "Xiao LL", "Ma XJ", "Yan YS", "Jiao PF"], "date": "2020-06-17T00:00:00Z", "doi": "10.2147/DDDT.S249557", "meta_date_publication": "2020", "meta_volume": "14", "meta_issue": "", "meta_pages": "2381-2392", "score": 50274.28, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ has a non-negligible role in @<m>DISEASE_Diabetes_Mellitus_Type_1</m> @DISEASE_MESH:D003922 @@@T1D@@@ treatment strategies. ", "citations": {"NLM": "Ren GF, Xiao LL, Ma XJ, Yan YS, Jiao PF. Metformin Decreases Insulin Resistance in Type 1 Diabetes Through Regulating p53 and RAP2A in vitro and in vivo Drug Des Devel Ther. 2020;14():2381-2392. PMID: 32606605", "BibTeX": "@article{32606605, title={Metformin Decreases Insulin Resistance in Type 1 Diabetes Through Regulating p53 and RAP2A in vitro and in vivo}, author={Ren GF and Xiao LL and Ma XJ and Yan YS and Jiao PF}, journal={Drug Des Devel Ther}, volume={14}, pages={2381-2392}}"}}, {"_id": "33981216", "pmid": 33981216, "pmcid": "PMC8107689", "title": "Analysis of Time Course and Dose Effect From Metformin on Body Mass Index in Children and Adolescents", "journal": "Front Pharmacol", "authors": ["Wang DD", "Mao YZ", "He SM", "Chen X"], "date": "2021-04-26T00:00:00Z", "doi": "10.3389/fphar.2021.611480", "meta_date_publication": "2021", "meta_volume": "12", "meta_issue": "", "meta_pages": "611480", "score": 50269.44, "text_hl": "In addition, for @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Diabetes_Mellitus_Type_1</m> @DISEASE_MESH:D003922 @@@type 1 diabetes mellitus@@@, 1,000 mg/day @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ was required for at least 25.2 weeks and 100.8 weeks to achieve the plateau of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ effect. ", "citations": {"NLM": "Wang DD, Mao YZ, He SM, Chen X. Analysis of Time Course and Dose Effect From Metformin on Body Mass Index in Children and Adolescents Front Pharmacol. 2021;12():611480. PMID: 33981216", "BibTeX": "@article{33981216, title={Analysis of Time Course and Dose Effect From Metformin on Body Mass Index in Children and Adolescents}, author={Wang DD and Mao YZ and He SM and Chen X}, journal={Front Pharmacol}, volume={12}, pages={611480}}"}}, {"_id": "37387358", "pmid": 37387358, "pmcid": "PMC10328035", "title": "Cardiometabolic risk factors, peripheral arterial tonometry and metformin in adults with type 1 diabetes participating in the REducing with MetfOrmin Vascular Adverse Lesions trial", "journal": "Diab Vasc Dis Res", "authors": ["Chen D", "Jenkins AJ", "Greenlaw N", "Dudman K", "Fernandes T", "Carty DM", "Hughes AD", "Januszewski AS", "Stehouwer CD", "Petrie JR"], "date": "2023-05-01T00:00:00Z", "doi": "10.1177/14791641231183634", "meta_date_publication": "2023 May-Jun", "meta_volume": "20", "meta_issue": "3", "meta_pages": "14791641231183634", "score": 50267.875, "text_hl": "Beneficial effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on vascular function have been reported in youth with @<m>DISEASE_Diabetes_Mellitus_Type_1</m> @DISEASE_MESH:D003922 @@@type 1 diabetes@@@ (@<m>DISEASE_Diabetes_Mellitus_Type_1</m> @DISEASE_MESH:D003922 @@@T1D@@@). ", "citations": {"NLM": "Chen D, Jenkins AJ, Greenlaw N, Dudman K, Fernandes T, Carty DM, Hughes AD, Januszewski AS, Stehouwer CD, Petrie JR. Cardiometabolic risk factors, peripheral arterial tonometry and metformin in adults with type 1 diabetes participating in the REducing with MetfOrmin Vascular Adverse Lesions trial Diab Vasc Dis Res. 2023 May-Jun;20(3):14791641231183634. PMID: 37387358", "BibTeX": "@article{37387358, title={Cardiometabolic risk factors, peripheral arterial tonometry and metformin in adults with type 1 diabetes participating in the REducing with MetfOrmin Vascular Adverse Lesions trial}, author={Chen D and Jenkins AJ and Greenlaw N and Dudman K and Fernandes T and Carty DM and Hughes AD and Januszewski AS and Stehouwer CD and Petrie JR}, journal={Diab Vasc Dis Res}, volume={20}, number={3}, pages={14791641231183634}}"}}, {"_id": "36992735", "pmid": 36992735, "pmcid": "PMC10012108", "title": "Interventions to Decrease Carotid-Intima Media Thickness in Children and Adolescents With Type 1 Diabetes: A Systematic Review and Meta-Analysis", "journal": "Front Clin Diabetes Healthc", "authors": ["Epure AM", "Anker D", "Di Bernardo S", "da Costa BR", "Sekarski N", "Chiolero A"], "date": "2022-07-04T00:00:00Z", "doi": "10.3389/fcdhc.2022.882504", "meta_date_publication": "2022", "meta_volume": "3", "meta_issue": "", "meta_pages": "882504", "score": 50264.473, "text_hl": "...The effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ compared with placebo on @GENE_CIMT @GENE_404677 @@@CIMT@@@ in children with @<m>DISEASE_Diabetes_Mellitus_Type_1</m> @DISEASE_MESH:D003922 @@@type 1 diabetes@@@. ", "citations": {"NLM": "Epure AM, Anker D, Di Bernardo S, da Costa BR, Sekarski N, Chiolero A. Interventions to Decrease Carotid-Intima Media Thickness in Children and Adolescents With Type 1 Diabetes: A Systematic Review and Meta-Analysis Front Clin Diabetes Healthc. 2022;3():882504. PMID: 36992735", "BibTeX": "@article{36992735, title={Interventions to Decrease Carotid-Intima Media Thickness in Children and Adolescents With Type 1 Diabetes: A Systematic Review and Meta-Analysis}, author={Epure AM and Anker D and Di Bernardo S and da Costa BR and Sekarski N and Chiolero A}, journal={Front Clin Diabetes Healthc}, volume={3}, pages={882504}}"}}, {"_id": "35620570", "pmid": 35620570, "pmcid": "PMC9130013", "title": "Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes", "journal": "J Diabetes Res", "authors": ["Janić M", "Cankar M", "Šmid J", "France Štiglic A", "Jerin A", "Šabovič M", "Janež A", "Lunder M"], "date": "2022-05-17T00:00:00Z", "doi": "10.1155/2022/6796470", "meta_date_publication": "2022", "meta_volume": "2022", "meta_issue": "", "meta_pages": "6796470", "score": 50264.035, "text_hl": "@CHEMICAL_empagliflozin @CHEMICAL_MESH:C570240 @@@Empagliflozin@@@-@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with @<m>DISEASE_Diabetes_Mellitus_Type_1</m> @DISEASE_MESH:D003922 @@@Type 1 Diabetes@@@", "citations": {"NLM": "Janić M, Cankar M, Šmid J, France Štiglic A, Jerin A, Šabovič M, Janež A, Lunder M. Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes J Diabetes Res. 2022;2022():6796470. PMID: 35620570", "BibTeX": "@article{35620570, title={Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes}, author={Janić M and Cankar M and Šmid J and France Štiglic A and Jerin A and Šabovič M and Janež A and Lunder M}, journal={J Diabetes Res}, volume={2022}, pages={6796470}}"}}, {"_id": "31670618", "pmid": 31670618, "title": "Metformin: Up to Date.", "journal": "Endocr Metab Immune Disord Drug Targets", "authors": ["Sciannimanico S", "Grimaldi F", "Vescini F", "De Pergola G", "Iacoviello M", "Licchelli B", "Guastamacchia E", "Giagulli VA", "Triggiani V"], "date": "2020-01-01T00:00:00Z", "doi": "10.2174/1871530319666190507125847", "meta_date_publication": "2020", "meta_volume": "20", "meta_issue": "2", "meta_pages": "172-181", "score": 50262.57, "text_hl": "We identified keywords and MeSH terms in Pubmed and the terms @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@, @<m>DISEASE_Diabetes_Mellitus_Type_1</m> @DISEASE_MESH:D003922 @@@type 1 diabetes@@@, pregnancy, @DISEASE_Heart_Failure @DISEASE_MESH:D006333 @@@heart failure@@@, @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@PCOS@@@, etc, were searched, selecting only significant original articles and review in English, in particular of the last five years. ", "citations": {"NLM": "Sciannimanico S, Grimaldi F, Vescini F, De Pergola G, Iacoviello M, Licchelli B, Guastamacchia E, Giagulli VA, Triggiani V. Metformin: Up to Date. Endocr Metab Immune Disord Drug Targets. 2020;20(2):172-181. PMID: 31670618", "BibTeX": "@article{31670618, title={Metformin: Up to Date.}, author={Sciannimanico S and Grimaldi F and Vescini F and De Pergola G and Iacoviello M and Licchelli B and Guastamacchia E and Giagulli VA and Triggiani V}, journal={Endocr Metab Immune Disord Drug Targets}, volume={20}, number={2}, pages={172-181}}"}}]}